N-benzyl-N-isopropyl-propanediyldiamine | 92106-90-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-benzyl-N-isopropyl-propanediyldiamine
• 英文别名: N-Benzyl-N-isopropyl-propandiyldiamin；N'-benzyl-N'-propan-2-ylpropane-1,3-diamine
• CAS: 92106-90-6
• 化学式: C₁₃H₂₂N₂
• mdl: MFCD09723556
• 分子量: 206.331
• InChiKey: BDHPJWSPJJFUKH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  乙醇酸乙酯 、 N-benzyl-N-isopropyl-propanediyldiamine 生成 N-[3-(benzyl-isopropyl-amino)-propyl]-glycolamide
  参考文献：
  名称：

  Aminoalkylamides and Oxazolidinediones¹

  摘要：

  DOI：

  10.1021/ja01521a043
• 作为产物：
  描述：

  N-benzyl-N-isopropyl-β-alanine nitrile 生成 N-benzyl-N-isopropyl-propanediyldiamine
  参考文献：
  名称：

  Aminoalkylamides and Oxazolidinediones¹

  摘要：

  DOI：

  10.1021/ja01521a043

文献信息

• Inhibitors of MshC and Homologs Thereof, and Methods of Identifying Same
  申请人：Fahey Robert C.

  公开号：US20100022509A1

  公开（公告）日：2010-01-28

  The present invention utilizes three families of bacterial enzymes, which play a key role in mycothiol biosynthesis. The three families are bacterial cysteine:glucosaminyl inositol ligases (MshC) with catalytic ligase activity for ligation of glucosaminyl inositol and cysteine, bacterial acetyl-CoA:Cys-GlcN-Ins acetyltransferases (MshD) with catalytic activity for addition of an acetyl group to Cys-GlcN-Ins and bacterial MshA glycosyltransferase with catalytic activity for production of GlcNAc-Ins. The invention provides methods for using the mycothiol biosynthesis ligases, acetyltransferases or glycosyltransferases in drug screening assays to determine compounds that inhibit activity. The invention also provides inhibitors of the production or activity of the enzymes of mycothiol biosynthesis, and use of the inhibitors for treating microbial infection.

  本发明利用三种细菌酶家族，它们在肌硫醇生物合成中起着关键作用。这三个家族是：具有催化配体活性的细菌半胱氨酸：葡萄糖胺酰肌醇连接酶（MshC），用于连接葡萄糖胺酰肌醇和半胱氨酸；具有催化活性的细菌乙酰辅酶A：半胱氨酸-GlcN-Ins乙酰转移酶（MshD），用于向Cys-GlcN-Ins添加乙酰基；以及具有催化活性的细菌MshA糖基转移酶，用于生产GlcNAc-Ins。本发明提供了使用肌硫醇生物合成连接酶、乙酰转移酶或糖基转移酶进行药物筛选测定的方法，以确定抑制活性的化合物。本发明还提供了肌硫醇生物合成酶的产生或活性的抑制剂，并将其用于治疗微生物感染。
• Chemokine receptor modulators
  申请人：Clark Michael P.

  公开号：US20080293711A1

  公开（公告）日：2008-11-27

  The invention provides compounds of Formula (I) and pharmaceutical compositions comprising compounds of Formula (I). These compounds are useful treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers.

  本发明提供了化合物(I)及包含化合物(I)的药物组合物。这些化合物可用于治疗或预防HIV感染，并用于治疗增殖性疾病，如抑制各种癌症的转移。
• NOVEL AGENTS OF CALCIUM ION CHANNEL MODULATORS
  申请人：VM Discovery, Inc.

  公开号：EP2073799A2

  公开（公告）日：2009-07-01
• US8586619B2
  申请人：——

  公开号：US8586619B2

  公开（公告）日：2013-11-19
• [EN] AZAHETEROCYCLES, COMBINATORY LIBRARY, FOCUSED LIBRARY, PHARMACEUTICAL COMPOSITION AND METHODS FOR THE PRODUCTION THEREOF<br/>[FR] BIBLIOTHÈQUES COMBINATOIRE ET FOCALISÉE D'AZAHÉTÉROCYCLES, COMPOSITION PHARMACEUTIQUE ET PROCÉDÉS DE LEUR FABRICATION
  申请人：CHEMICAL DIVERSITY RES INST LT

  公开号：WO2007117180A1

  公开（公告）日：2007-10-18

  [EN] The invention relates to novel azaheterocycles of interest as potential physiologically active substances (agonists, antagonists, receptor modulators, ferment inhibitors, oncolytics, antibacterial and antiparasitic agent etc.), to combinatory and focused libraries comprising novel azaheterocycles of a pharmaceutical composition containing said novel azaheterocycles in the form of an active substance and to methods for the production and the use thereof. Said novel azaheterocycles are of general formula (1), wherein W is an azaheterocycle which comprises 6-12 atoms, is optionally annelated, has at least one C₅-C₇ carbocycle and/or heterocycle, and also comprises at least one of heteroatoms and is selected from an O, S or N group; R₁
  [FR] L'invention concerne de nouveaux azahétérocycles qui représentent un intérêt certain en tant que substances physiologiquement actives potentielles (agonistes, antagonistes et modulateurs de récepteurs, inhibiteurs de ferments, oncolytiques, antibactériens, antiparasitaires, etc.), des bibliothèques combinatoire et focalisée comprenant de nouveaux azahétérocycles, une composition pharmaceutique contenant en tant que substance active de nouveaux azahétérocycles, leurs procédés de fabrication et d'utilisation. L'invention porte sur de nouveaux azahétérocycles ayant la formule générale (1), dans laquelle W est un hétérocycle comprenant de 6 à 12 atomes éventuellement hybridé à un carbocycle et/ou hétérocycle C₅-C₇, qui comprend au moins un hétéro-atome sélectionné dans le groupe O, S ou N, R₁